المؤلفون: Jessica W. Chen, William Jacot, Javier Cortés, Ian E. Krop, Susan Dent, Nadia Harbeck, Michelino De Laurentiis, Véronique Diéras, Young‐Hyuck Im, Thomas J. Stout, Frauke Schimmoller, Heidi M. Savage, Katherine E. Hutchinson, Timothy R. Wilson

المصدر: Molecular Oncology, Vol 17, Iss 10, Pp 2000-2016 (2023)

مصطلحات موضوعية: breast cancer, circulating tumour DNA, PIK3CA, SANDPIPER, taselisib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1574-7891Test; https://doaj.org/toc/1878-0261Test

الوصول الحر: https://doaj.org/article/535a6a7921404a8298c1f95b55637007Test

المؤلفون: Katherine E. Hutchinson, Jessica W. Chen, Heidi M. Savage, Thomas J. Stout, Frauke Schimmoller, Javier Cortés, Susan Dent, Nadia Harbeck, William Jacot, Ian Krop, Sally E. Trabucco, Smruthy Sivakumar, Ethan S. Sokol, Timothy R. Wilson

المصدر: Genome Medicine, Vol 15, Iss 1, Pp 1-14 (2023)

مصطلحات موضوعية: PIK3CA, Double PIK3CA mutation, Clonal, Taselisib, PI3K inhibitor, Breast cancer, Medicine, Genetics, QH426-470

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1756-994XTest

الوصول الحر: https://doaj.org/article/6a84c1824dfc43c99cd063f56d446e86Test

المؤلفون: V. V. Vorotnikov, R. A. Pakhomova, A. V. Soinov, A. S. Gunina, I. V. Kopytich, M. G. Tsoi, S. A. Abdugafforov, В. В. Воротников, Р. А. Пахомова, А. В. Сойнов, А. С. Гунина, И. В. Копытич, М. Г. Цой, С. А. Абдугаффоров

المصدر: Creative surgery and oncology; Том 12, № 3 (2022); 199-204 ; Креативная хирургия и онкология; Том 12, № 3 (2022); 199-204 ; 2076-3093 ; 2307-0501

مصطلحات موضوعية: палбоциклиб, neoadjuvant chemotherapy, neoadjuvant hormone therapy, triple negative breast neoplasm, gene expression profiling, tamoxifen, letrozole, taselisib, palbocyclib, неоадъювантная химиотерапия, неоадъювантная гормонотерапия, тройное негативное новообразование молочной железы, профилирование генной экспрессии, тамоксифен, летрозол, таселисиб

وصف الملف: application/pdf

العلاقة: https://www.surgonco.ru/jour/article/view/714/506Test; Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. DOI:10.3322/caac.21660; Australian Institute of Health and Welfare 2019. Cancer in Australia 2019. Cancer series no.119. Cat. no. CAN 123. Canberra: AIHW; 2019.; Puglisi F., Follador A., Minisini A.M., Cardellino G.G., Russo S., Andreetta C., et al. Baseline staging tests after a new diagnosis of breast cancer: Further evidence of their limited indications. Ann. Oncol. 2005;16:263–6. DOI:10.1093/annonc/mdi063; Liedtke C., Mazouni C., Hess K.R., André F., Tordai A., Mejia J.A., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008;26:1275–81. DOI:10.1200/JCO.2007.14.4147; Cortazar P., Zhang L., Untch M., Mehta K., Costantino J.P., Wolmark N., et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 2014;384:164–72. DOI:10.1016/S0140-6736(13)62422-8; Gianni L., Pienkowski T., Im Y.-H., Roman L., Tseng L.-M., Liu M.-C., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32. DOI:10.1016/S1470-2045(11)70336-9; Korde L.A., Somerfield M.R., Carey L.A., Crews J.R., Denduluri N., Hwang E.S., et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO Guideline. J Clin Oncol. 2021;39(13):1485–505. DOI:10.1200/JCO.20.03399; van Ramshorst M.S., van der Voort A., van Werkhoven E.D., Mandjes I.A., Kemper I., Dezentjé V.O., et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1630–40. DOI:10.1016/S1470-2045(18)30570-9; Zhang D., Lu W., Zhuo Z., Mei H., Wu X., Cui Y. Construction of a breast cancer prognosis model based on alternative splicing and immune infiltration. Discov Oncol. 2022;13(1):78. DOI:10.1007/s12672-022-00506-0; Fujii T., Kogawa T., Dong W., Sahin A.A., Moulder S., Litton J.K., et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol. 2017;28(10):2420–8. DOI:10.1093/annonc/mdx397; Schneeweiss A., Chia S., Hickish T., Harvey V., Eniu A., Hegg R., et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA) Ann. Oncol. 2013;24:2278–84. DOI:10.1093/annonc/mdt182; Sikov W.M., Berry D.A., Perou C.M., Singh B., Cirrincione C.T., Tolaney S.M., et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance) J. Clin. Oncol. 2015;33:13–21. DOI:10.1200/jco.2014.57.0572; Ellis M.J., Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat. 2007;105(Suppl 1):33–43. DOI:10.1007/s10549-007-9701-x; Smith I.E., Dowsett M., Ebbs S.R., Dixon J.M., Skene A., Blohmer J.U., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23(22):5108–16. DOI:10.1200/JCO.2005.04.005; Cataliotti L., Buzdar A.U., Noguchi S., Bines J., Takatsuka Y., Petrakova K., et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer. 2006;106(10):2095–103. DOI:10.1002/cncr.21872; Ellis M.J., Suman V.J., Hoog J., Lin L., Snider J., Prat A., et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–9. DOI:10.1200/JCO.2010.31.6950; Spring L.M., Gupta A., Reynolds K.L., Gadd M.A., Ellisen L.W., Isakoff S.J., et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1477–86. DOI:10.1001/jamaoncol.2016.1897; Semiglazov V.F., Semiglazov V.V., Dashyan G.A., Ziltsova E.K., Ivanov V.G., Bozhok A.A., et al. Phase 2 randomized trial of primary endocrine therapy vs chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110:244–54. DOI:10.1002/cncr.22789; Alba E., Calvo L., Albanell J., De La Haba J.R., Lanza A.A., Chacon J.I., et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: Results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann. Oncol. 2012;23:3069–74. DOI:10.1093/annonc/mds132; Murray N., Francis P., Zdenkowski N., Wilcken N., Boyle F., Gebski V., et al. Randomized trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy to downstage ER+ve breast cancer: Breast Cancer Trials Group ANZ 1401 ELIMINATE trial. Ann Oncol. 2022;33(3):164–5. DOI:10.1016/j.annonc.2022.03.107; Krainick-Strobel U.E., Lichtenegger W., Wallwiener D., Tulusan A.H., Janicke F., Bastert G., et al. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer. 2008;8:62. DOI:10.1186/1471-2407-8-62; Llombart-Cussac A., Guerrero A., Galan A., Caranana V., Buch E., Rodriguez-Lescure A., et al. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. Clin Transl Oncol. 2012;14(2):125–31. DOI:10.1007/s12094-012-0771-9; Carpenter R., Doughty J.C., Cordiner C., Moss N., Gandhi A., Wilson C., et al. Optimum duration of neoadjuvant letrozole to permit breast conserving surgery. Breast Cancer Res Treat. 2014;144(3):569–76. DOI:10.1007/s10549-014-2835-8; Prat A., Saura C., Pascual T., Hernando C., Munoz M., Pare L., et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):33–43. DOI:10.1016/S1470-2045(19)30786-7; Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thurlimann B., et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2016;24(9):2206–23. DOI:10.1093/annonc/mdt303; Harbeck N., Thomssen C., Gnant M. St. Gallen 2013: brief preliminary summary of the consensus discussion. Breast Care (Basel). 2013;8(2):102–9. DOI:10.1159/000351193; Burstein H.J., Curigliano G., Loibl S., Dubsky P., Gnant M., Poortmans P., et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541–57. DOI:10.1093/annonc/mdz235; Burstein H.J., Curigliano G., Thürlimann B., Weber W.P., Poortmans P., Regan M.M., et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32(10):1216–35. DOI:10.1016/j.annonc.2021.06.023; Lin M., Jin Y., Zhang J. Expert review on systemic treatment in the St. Gallen International Breast Cancer Conference 2021. Transl Breast Cancer Res 2021;2:17. DOI:10.21037/tbcr-21-7; Jackisch C. Overcoming endocrine resistance in neoadjuvant endocrine therapy for early breast cancer. Lancet Oncol. 2019;20(9):1185–7. DOI:10.1016/S1470-2045(19)30500-5; Saura C., Hlauschek D., Oliveira M., Zardavas D., Jallitsch-Halper A., de la Pena L., et al. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2019;20(9):1226–38. DOI:10.1016/S1470-2045(19)30334-1; Johnston S., Puhalla S., Wheatley D., Ring A., Barry P., Holcombe C., et al. Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial. J Clin Oncol. 2019;37(3):178–89. DOI:10.1200/JCO.18.01624; Cottu P., D'Hondt V., Dureau S., Lerebours F., Desmoulins I., Heudel P.E., et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol. 2018;29(12):2334–40. DOI:10.1093/annonc/mdy448; Sestak I., Buus R., Cuzick J., Dubsky P., Kronenwett R., Denkert C., et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4(4):545–53. DOI:10.1001/jamaoncol.2017.5524; Jaber M.I., Song B., Taylor C., Vaske C.J., Benz S.C., Rabizadeh S., et al. A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival. Breast Cancer Res. 2020;22(1):12. DOI:10.1186/s13058-020-1248-3; Andre F., Ismaila N., Allison K.H., Barlow W.E., Collyar D.E., Damodaran S., et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO Guideline Update. J Clin Oncol. 2022;40(16):1816–37. DOI:10.1200/JCO.22.00069; Wu H.J., Chu P.Y. Recent discoveries of macromolecule- and cell-based biomarkers and therapeutic implications in breast cancer. Int J Mol Sci. 2021;22(2):636. DOI:10.3390/ijms22020636; Goto-Yamaguchi L., Yamamoto-Ibusuki M., Yamamoto Y., Fujiki Y., Tomiguchi M., Sueta A., et al. Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling. Breast Cancer Res Treat. 2018;172(2):353–62. DOI:10.1007/s10549-018-4933-5; Gao J.J., Swain S.M. Luminal a breast cancer and molecular assays: a review. Oncologist. 2018;23(5):556–65. DOI:10.1634/theoncologist.2017-0535; Cardoso F., Kyriakides S., Ohno S., Penault-Llorca F., Poortmans P., Rubio I.T., et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(10):1674. DOI:10.1093/annonc/mdz173; Selli C., Turnbull A.K., Pearce D.A., Li A., Fernando A., Wills J., et al. Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours. Breast Cancer Res. 2019;21(1):2. DOI:10.1186/s13058-018-1089-5; Inda M.A., Blok E.J., Kuppen P.J.K., Charehbili A., den Biezen-Timmermans E.C., van Brussel A., et al. Estrogen Receptor pathway activity score to predict clinical response or resistance to neo-adjuvant endocrine therapy in primary breast cancer. Mol Cancer Ther. 2019;19(2):680–89. DOI:10.1158/1535-7163.MCT-19-0318; Ueno T., Saji S., Masuda N., Iwata H., Kuroi K., Sato N., et al. Changes in recurrence score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. ESMO Open. 2019;4(1):e000476. DOI:10.1136/esmoopen-2018-000476; Vendrell J.A., Solassol J., Gyorffy B., Vilquin P., Jarlier M., Donini C.F., et al. Evaluating ZNF217 mRNA expression levels as a predictor of response to endocrine therapy in ER+ breast cancer. Front Pharmacol. 2018;9:1581. DOI:10.3389/fphar.2018.01581; Bear H.D., Wan W., Robidoux A., Rubin P., Limentani S., White R.L. Jr, et al. Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: a multicenter trial. J Surg Oncol. 2017;115(8):917–23. DOI:10.1002/jso.24610; Sparano J.A., Gray R.J., Makower D.F., Pritchard K.I., Albain K.S., Hayes D.F., et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–21. DOI:10.1056/NEJMoa1804710; Russnes H.G., Lingjaerde O.C., Borresen-Dale A.L., Caldas C. Breast cancer molecular stratification: from intrinsic subtypes to integrative clusters. Am J Pathol. 2017;187(10):2152–62. DOI:10.1016/j.ajpath.2017.04.022; Giridhar K.V., Liu M.C. Available and emerging molecular markers in the clinical management of breast cancer. Expert Rev Mol Diagn. 2019;19(10):919–28. DOI:10.1080/14737159.2019.1664901; Gyorffy B., Hatzis C., Sanft T., Hofstatter E., Aktas B., Pusztai L. Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res. 2017;17:11. DOI:10.1186/s13058-015-0514-2; Iwata H., Masuda N., Yamamoto Y., Fujisawa T., Toyama T., Kashiwaba M., et al. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. Breast Cancer Res Treat. 2019;173(1):123–33. DOI:10.1007/s10549-018-4964-y; https://www.surgonco.ru/jour/article/view/714Test

الإتاحة: https://doi.org/10.24060/2076-3093-2022-12-3-199-204Test
https://doi.org/10.3322/caac.21660Test
https://doi.org/10.1093/annonc/mdi063Test
https://doi.org/10.1200/JCO.2007.14.4147Test
https://doi.org/10.1016/S0140-6736Test(13)62422-8
https://doi.org/10.1016/S1470-2045Test(11)70336-9
https://doi.org/10.1200/JCO.20.03399Test
https://doi.org/10.1016/S1470-2045Test(18)30570-9
https://doi.org/10.1007/s12672-022-00506-0Test
https://doi.org/10.1093/annonc/mdx397Test

المؤلفون: Grinshpun, A, Ren, S, Graham, N, DeMeo, M K, Wrabel, E, Carter, J, Tayob, N, Pereslete, A, Hamilton, E, Juric, D, Mayer, E L, Tolaney, S M, Krop, I E, Metzger, O

المصدر: ESMO Open ; ISSN:2059-7029 ; Volume:9 ; Issue:6

مصطلحات موضوعية: HER2, PIK3CA, ctDNA, metastatic breast cancer, taselisib

العلاقة: https://doi.org/10.1016/j.esmoop.2024.103465Test; https://pubmed.ncbi.nlm.nih.gov/38833970Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179085Test/

الإتاحة: https://doi.org/10.1016/j.esmoop.2024.103465Test
https://pubmed.ncbi.nlm.nih.gov/38833970Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179085Test/

المؤلفون: Chen J. W., Jacot W., Cortes J., Krop I. E., Dent S., Harbeck N., De Laurentiis M., Dieras V., Im Y. -H., Stout T. J., Schimmoller F., Savage H. M., Hutchinson K. E., Wilson T. R.

المساهمون: Chen, J. W., Jacot, W., Cortes, J., Krop, I. E., Dent, S., Harbeck, N., De Laurentiis, M., Dieras, V., Im, Y. -H., Stout, T. J., Schimmoller, F., Savage, H. M., Hutchinson, K. E., Wilson, T. R.

مصطلحات موضوعية: PIK3CA, SANDPIPER, breast cancer, circulating tumour DNA, taselisib

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000958676100001; journal:MOLECULAR ONCOLOGY; https://hdl.handle.net/11588/922326Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85150959068

الإتاحة: https://doi.org/10.1002/1878-0261.13416Test
https://hdl.handle.net/11588/922326Test

المؤلفون: Marc Bardou, Pierre Vabres, Laurence Faivre, Annabel Maruani, Victoria E R Parker, A. Phan, Christine Chiaverini, L. Martin, Jill Clayton-Smith, C. Fleck, Maxime Luu, Tristan Mirault, Fanny Morice-Picard, M. Carpentier, Marie-Line Jacquemont, Hervé Devilliers, Marjolaine Willems, A. Maurer, Romaric Loffroy, Didier Bessis, Florence Petit, Robert K. Semple, M. Yousfi

المساهمون: Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques (CIC-EC), Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Institut National de la Santé et de la Recherche Médicale (INSERM), FHU TRANSLAD (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre de Référence des Maladies Génétiques à Expression Cutanée (MAGEC), Service de médecine interne et maladies systémiques (SOC 2) [CHU de Dijon], Service de radiologie et d'Imagerie médicale diagnostique et thérapeutique (CHU de Dijon), Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Hospices Civils de Lyon (HCL), Institute of Applied Physics [Bern] (IAP), University of Bern, CHU Bordeaux [Bordeaux], Centre de Référence Maladies Rares Anomalies du Développement et Syndromes Malformatifs Nord, Centre Hospitalier Universitaire de Lille (CHU de Lille), Hôpital Lapeyronie [Montpellier] (CHU), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), Centre Hospitalier Universitaire de Nice (CHU Nice), Centre national de référence des maladies vasculaires rares, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), University of Manchester [Manchester], CHU Dijon, AstraZeneca [Cambridge, UK], University of Edinburgh, Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement

المصدر: Genetics in Medicine
Genetics in Medicine, Nature Publishing Group, 2021, ⟨10.1038/s41436-021-01290-y⟩
Luu, M, Vabres, P, Devilliers, H, Loffroy, R, Phan, A, Martin, L, Morice-Picard, F, Petit, F, Willems, M, Bessis, D, Jacquemont, M-L, Maruani, A, Chiaverini, C, Mirault, T, Clayton-Smith, J, Carpentier, M, Fleck, C, Maurer, A, Yousfi, M, Parker, V E R, Semple, R K, Bardou, M & Faivre, L 2021, ' Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and KLIPPEL TRENAUNAY SYNDROME (KTS): the TOTEM trial, a phase 1/2 multicentre, open-label, single-arm study ', Genetics in Medicine . https://doi.org/10.1038/s41436-021-01290-yTest

مصطلحات موضوعية: Adult, Klippel-Trenaunay-Weber Syndrome, medicine.medical_specialty, Klippel-Trenaunay syndrome, Syzygium, [SDV]Life Sciences [q-bio], Population, Overgrowth syndrome, Article, Phosphatidylinositol 3-Kinases, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Internal medicine, taselisib, medicine, Humans, education, Adverse effect, Genetics (clinical), education.field_of_study, business.industry, Imidazoles, clinical trial, PIK3CA, medicine.disease, 3. Good health, Clinical trial, Oxazepines, Tolerability, 030220 oncology & carcinogenesis, Mutation, Cohort, Quality of Life, mosaic, business, PROS treatment

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cb35a651c9d3e22a4c1a05d557c9a14Test
https://doi.org/10.1038/s41436-021-01290-yTest

المؤلفون: J.Y. Hsu, Na Cui, Susan Dent, Sofia Sousa, Timothy R. Wilson, Véronique Diéras, William Jacot, Ian E. Krop, Frauke Schimmoller, M. De Laurentiis, Nadia Harbeck, Yunjoo Im, Jing He, J. Cortes, Pamela Drullinsky

المساهمون: Dent, S., Cortes, J., Im, Y. -H., Dieras, V., Harbeck, N., Krop, I. E., Wilson, T. R., Cui, N., Schimmoller, F., Hsu, J. Y., He, J., De Laurentiis, M., Sousa, S., Drullinsky, P., Jacot, W.

المصدر: Annals of Oncology. 32:197-207

مصطلحات موضوعية: 0301 basic medicine, Receptor, ErbB-2, PIK3CA mutation, Gastroenterology, law.invention, Phosphatidylinositol 3-Kinases, 0302 clinical medicine, Randomized controlled trial, law, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Fulvestrant, Class I Phosphatidylinositol 3-Kinase, advanced breast cancer, education.field_of_study, Hazard ratio, Imidazoles, Hematology, Receptors, Estrogen, Oncology, 030220 oncology & carcinogenesis, Female, Breast Neoplasm, Human, medicine.drug, medicine.medical_specialty, Class I Phosphatidylinositol 3-Kinases, medicine.drug_class, Population, Breast Neoplasms, PI3K inhibitor, Placebo, 03 medical and health sciences, Internal medicine, taselisib, medicine, Humans, education, Adverse effect, Imidazole, Antineoplastic Combined Chemotherapy Protocol, Aromatase inhibitor, Oxazepine, business.industry, Oxazepines, 030104 developmental biology, Quality of Life, Phosphatidylinositol 3-Kinase, Neoplasm Recurrence, Local, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bdee42c75cb939356b9f98869998bcaTest
https://doi.org/10.1016/j.annonc.2020.10.596Test

المؤلفون: Morgillo, Floriana, Della Corte, Carminia Maria, Diana, Anna, di Mauro, Concetta, Ciaramella, Vincenza, Barra, Giusi, Belli, Valentina, Franzese, Elisena, Bianco, Roberto, Maiello, Evaristo, De Vita, Ferdinando, Ciardiello, Fortunato, Orditura, Michele

المساهمون: Morgillo, Floriana, Della Corte, Carminia Maria, Diana, Anna, di Mauro, Concetta, Ciaramella, Vincenza, Barra, Giusi, Belli, Valentina, Franzese, Elisena, Bianco, Roberto, Maiello, Evaristo, De Vita, Ferdinando, Ciardiello, Fortunato, Orditura, Michele

مصطلحات موضوعية: AKT, Breast cancer, Ipatasertib, Novel drug, Taselisib, Oncology

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/29100327; info:eu-repo/semantics/altIdentifier/wos/WOS:000412066700060; volume:8; issue:44; firstpage:76479; lastpage:76491; numberofpages:13; journal:ONCOTARGET; http://hdl.handle.net/11591/385350Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85030325748; http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=20385&path%5B%5D=64973Test

الإتاحة: https://doi.org/10.18632/oncotarget.20385Test
http://hdl.handle.net/11591/385350Test
http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=20385&path%5B%5D=64973Test

المؤلفون: Dent S., Cortes J., Im Y. -H., Dieras V., Harbeck N., Krop I. E., Wilson T. R., Cui N., Schimmoller F., Hsu J. Y., He J., De Laurentiis M., Sousa S., Drullinsky P., Jacot W.

المساهمون: Dent, S., Cortes, J., Im, Y. -H., Dieras, V., Harbeck, N., Krop, I. E., Wilson, T. R., Cui, N., Schimmoller, F., Hsu, J. Y., He, J., De Laurentiis, M., Sousa, S., Drullinsky, P., Jacot, W.

مصطلحات موضوعية: advanced breast cancer, PI3K inhibitor, PIK3CA mutation, taselisib, Antineoplastic Combined Chemotherapy Protocol, Class I Phosphatidylinositol 3-Kinase, Female, Fulvestrant, Human, Imidazole, Neoplasm Recurrence, Local, Oxazepine, Phosphatidylinositol 3-Kinase, Quality of Life, Receptor, ErbB-2, Breast Neoplasm, Receptors, Estrogen

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000608030000010; volume:32; issue:2; firstpage:197; lastpage:207; numberofpages:11; journal:ANNALS OF ONCOLOGY; http://hdl.handle.net/11588/844157Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85096964500

الإتاحة: https://doi.org/10.1016/j.annonc.2020.10.596Test
http://hdl.handle.net/11588/844157Test

المؤلفون: Andrés Cervantes, Hans Wildiers, Michael C. Wei, Mafalda Oliveira, Carlos Becerra, Cristina Saura, John Bond, Heather M. Moore, Stephen Lane Richey, Todd M. Bauer, Ian E. Krop, Timothy R. Wilson, Philippe L. Bedard, Manish R. Patel, Vandana G Abramson, Na Cui, Eric Reyner

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Lung Neoplasms, Receptor, ErbB-2, Docetaxel, PI3K, chemistry.chemical_compound, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis, Aged, 80 and over, Taselisib, Imidazoles, Middle Aged, Metastatic breast cancer, Treatment Outcome, Paclitaxel, 030220 oncology & carcinogenesis, Female, medicine.drug, Adult, medicine.medical_specialty, Maximum Tolerated Dose, Class I Phosphatidylinositol 3-Kinases, Breast Neoplasms, PI3K inhibitor, 03 medical and health sciences, Breast cancer, Pharmacokinetics, Internal medicine, medicine, Humans, Adverse effect, Aged, Taxane, business.industry, Capsule, PIK3CA, medicine.disease, Survival Analysis, Oxazepines, 030104 developmental biology, chemistry, Mutation, business, GDC-0032

وصف الملف: Print-Electronic

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f39f99cf25167457215cd64d3bc8206Test
https://lirias.kuleuven.be/handle/123456789/640324Test